Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sodium alginate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Sodium alginate. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-005261-69 Sponsor Protocol Number: GA1402 Start Date*: 2015-08-06
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A multi-centre, randomised, double-blind, two arm, parallel group, placebo-controlled study to assess the effect of Sodium Alginate Chewable Tablets on symptoms of gastro-oesophageal reflux disease.
    Medical condition: Gastro-Oesophageal Reflux Disease (GORD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003174-17 Sponsor Protocol Number: GA1405 Start Date*: 2015-03-24
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled pivotal study to assess the effect of a sodium alginate liquid suspension as add-on therapy in GORD patients wit...
    Medical condition: Gastro-Oesophageal Reflux Disease (GORD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006413-25 Sponsor Protocol Number: GA0821 Start Date*: 2008-12-09
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A single-centre randomised, partially blind, single dose, crossover study investigating the onset of action of soothing and cooling after taking Gaviscon Peppermint liquid, Double Action Gaviscon ...
    Medical condition: Symptoms of heartburn
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005821-31 Sponsor Protocol Number: GA0706 Start Date*: 2008-01-15
    Sponsor Name:Reckitt Benckiser Healthcare UK) Limited [...]
    1. Reckitt Benckiser Healthcare UK) Limited
    2. Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A single-centre randomised, partially blind, single dose, crossover pilot study investigating the use of stopwatches to assess the onset of action of soothing and cooling of Gaviscon Peppermint Liq...
    Medical condition: Symptoms of heartburn
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003158-15 Sponsor Protocol Number: GA1406 Start Date*: 2014-10-10
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, assessor blind, placebo controlled exploratory study in healthy volunteers, to characterise the acid neutralisation activity of sodium alginate oral suspension in the fasted state, us...
    Medical condition: To pilot the use of a custom designed pH catheter for the measurement of intragastric pH to characterise the antacid action of Gaviscon Double Action versus placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000678-44 Sponsor Protocol Number: GA1116 Start Date*: 2012-09-04
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj...
    Medical condition: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000539-42 Sponsor Protocol Number: RB2-NL-1518 Start Date*: 2016-04-15
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th...
    Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002341-35 Sponsor Protocol Number: GA1103 Start Date*: 2011-07-21
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A randomised single dose two cohort study comparing the speed of raft formation assessed by gamma scintigraphy in healthy volunteers following administration of a single dose of Gaviscon® Strawberr...
    Medical condition: To measure the formation and retention of alginate rafts in healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021630-63 Sponsor Protocol Number: GA1001 Start Date*: 2011-03-28
    Sponsor Name:Reckitt Benckiser
    Full Title: A randomised, double blind placebo controlled study in patients with reflux symptoms to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Peppermint liquid’ using the BRAVO...
    Medical condition: Gastro-oesophageal reflux disease (GORD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004062-17 Sponsor Protocol Number: NEK/MD/0119 Start Date*: 2020-12-03
    Sponsor Name:Nekkar Lab srl
    Full Title: OPEN, COMPARATIVE STUDY TO EVALUATE THE PERFORMANCE AND SAFETY OF THE MEDICAL DEVICE MARIAL® IN ASSOCIATION WITH PROTON-PUMP INHIBITORS VERSUS PPI ALONE IN PATIENTS AFFECTED BY GASTROESOPHAGEAL REF...
    Medical condition: gastroesophageal reflux disease (GERD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000844-13 Sponsor Protocol Number: SMR-2984 Start Date*: 2014-09-25
    Sponsor Name:Algipharma AS
    Full Title: A double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002125-35 Sponsor Protocol Number: SMR-2591 Start Date*: 2014-12-18
    Sponsor Name:Algipharma AS
    Full Title: A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization ...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019414-24 Sponsor Protocol Number: GA0921 Start Date*: 2010-07-09
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single centre, randomised, partially-blind, placebo-controlled 3 way crossover pilot study investigating efficacy in terms of heartburn relief after taking (2x250mg) Gaviscon® chewable tablets...
    Medical condition: Investigating efficacy in terms of heatburn relief in healthy subjects following a refluxogenic meal.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004725-27 Sponsor Protocol Number: GA1109 Start Date*: 2012-01-24
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid a...
    Medical condition: To pilot the use of a novel pH catheter for the measurement of oesophageal and intragastric pH comparing the onset and duration of antacid action of Gaviscon Double Action versus placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023090-19 Sponsor Protocol Number: SMR 2375 Start Date*: 2011-03-29
    Sponsor Name:AlgiPharma AS
    Full Title: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subje...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019072-68 Sponsor Protocol Number: version 1 (07/10/2010) Start Date*: 2010-12-31
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
    Full Title: A randomised, double blind, crossover study to determine the mechanism of action of Gaviscon Advance in Gastro-Oesophageal Reflux Disease (GORD)
    Medical condition: Gastro-oesophageal reflux disease (GORD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004109-28 Sponsor Protocol Number: GA1211 Start Date*: 2013-01-18
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A randomised, 4 way crossover, double blind, placebo controlled pilot study in patients with reflux symptoms, to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Mint ’ us...
    Medical condition: This study assesses suppression of gastro-oesophageal reflux of Gaviscon in patients with gastro-oesophageal reflux disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002188-84 Sponsor Protocol Number: GA1203 Start Date*: 2012-07-27
    Sponsor Name:Reckitt Benckiser Healthcare (UK) LTD
    Full Title: A multi-centred, randomised, double-blind, two arm, parallel group, placebo-controlled, pilot study to assess the effect of Gaviscon Double Action Tablets in patients with reflux disease
    Medical condition: This pilot study of Gaviscon Double Action Tablets is to be conducted to demonstrate that Gaviscon Double Action Tablets are effective in managing the symptoms of heartburn, acid regurgitation and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004131-23 Sponsor Protocol Number: GA1212 Start Date*: 2013-01-18
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, 2 way crossover, double blind, placebo controlled study in healthy volunteers, to characterise the antacid activity of Gaviscon Double Action Mint Liquid in the fasted ...
    Medical condition: This study is to demonstrate the antacid action of Gaviscon Double Action Mint versus a matched placebo using a pH catheter.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005486-21 Sponsor Protocol Number: GA1102 Start Date*: 2012-01-26
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd.
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled, pilot study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate respons...
    Medical condition: Gastro Oesophageal Reflux Disease (GORD)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:11:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA